Official Press Release
Guangdong Dongyang Pharmaceutical Co., Ltd. Honored with Guangdong Provincial Science and Technology Progress Award for Breakthrough in Anti-Infective Drug Development

Guangzhou, China – Guangdong Dongyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Dongyang Pharma") has been awarded the First Prize of the 2023 Guangdong Provincial Science and Technology Progress Award for its pioneering project titled Key Technological Innovations and Industrialization of Anti-Infective Drug Research and Development. This prestigious recognition, conferred by the Department of Science and Technology of Guangdong Province, underscores the company’s exceptional contributions to addressing global public health challenges through scientific innovation.

Project Background and Significance

Infectious diseases account for over 25% of global mortality (WHO, 2020), with annual healthcare expenditures for moderate-to-severe infections exceeding $570 billion. Viral hepatitis and influenza remain among the most prevalent infectious diseases in China, while antimicrobial resistance and severe bacterial infections pose escalating threats to public health. Dongyang Pharma’s project addresses three critical scientific challenges:

1. Original Drug Development: Pioneering novel anti-infective therapies to combat drug-resistant pathogens.
2. Preclinical Evaluation: Establishing advanced in vitro and in vivo models for efficacy and safety assessment.
3. Industrialization Breakthroughs: Optimizing scalable synthesis and production processes for global accessibility.

Key Achievements

• Intellectual Property: Secured 160 authorized patents (including 90 international patents) and published 37 peer-reviewed research papers.
• Pipeline Milestones: Advanced 9 Class 1 innovative drugs into clinical trials; Oseltamivir (branded as Kewei), a WHO-recommended influenza treatment, holds over 50% of the global erythromycin API market, supplying leading pharmaceutical companies such as Abbott and Pfizer.
• Commercial Impact: Generated over RMB 6.6 billion in revenue over the past three years; Kewei series products are utilized in over 1,000 tertiary hospitals nationwide, including Peking Union Medical College Hospital and Sun Yat-sen University-affiliated institutions.

Corporate Vision and Strategic Growth

Since its establishment in 2003, Dongyang Pharma has prioritized innovation and globalization, evolving into a fully integrated pharmaceutical enterprise with end-to-end capabilities in R&D, production, and commercialization. The company’s diversified pipeline spans infectious diseases, chronic conditions, and oncology, featuring:

• 45 Class 1 innovative drugs in development.
• 3 New Drug Applications (NDAs) under regulatory review.
• 10 candidates in Phase II/III clinical trials.

Dr. Zhang Yingjun, Chairman of Dongyang Pharma, stated: "This accolade reaffirms our commitment to advancing healthcare through scientific excellence. As we expand our global footprint, we remain dedicated to delivering transformative therapies that address the world’s most pressing medical needs."

Recent Strategic Milestones

• Collaboration with 3SBio: In November 2024, Dongyang Pharma partnered with 3SBio Inc. to commercialize benzenesulfonic acid creflotinib, a next-generation FLT3 inhibitor for acute myeloid leukemia (AML), in mainland China.
• Merger Completion: On August 7, 2025, the company finalized its merger with Dongyang Changjiang Pharmaceutical, solidifying its position as a listed entity on the Hong Kong Stock Exchange (Stock Code: 06887.HK).